Figure S6 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EGFR 19Del/C797S, EGFR 19Del/T790M/C797S and patient-derived xenograft models. The patient-derived xenograft was derived from a patient with poorly-differentiated adenocarcinoma harboring an EGFR 19Del/T790M/C797S mutation. B, BBT-176 activity in a LU1235 EGFR 19Del patient-derived xenograft model. Abbreviations: PDX, patient-derived xenograft; PO, orally; QD, once daily.